EUVIMEDScopri EUVIMED
Open access · CC BY 4.0

A Tumor and Immune-Related Micro-RNA Signature Predicts Relapse-Free Survival of Melanoma Patients Treated with Ipilimumab

Iyad Kobeissi, Islam Eljilany iD, Tala Achkar, William A LaFramboise, Lucas Santana-Santos iD, Ahmad A Tarhini

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24098167 ↗

At a glance

Journal article in International Journal of Molecular Sciences, 2023. Written by Iyad Kobeissi and 5 co-authors. Institution: Cutaneous Oncology and Immunology Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. Major MEDLINE topics: MicroRNAs, Melanoma. Cited 6 times so far (Crossref); 47 references. The full text is freely available (open access, CC BY 4.0). Funded by: Moffitt Cancer Center, NCI NIH HHS, University of Pittsburgh.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Despite the unprecedented advances in the treatment of melanoma with immunotherapy, there continues to be a major need for biomarkers of clinical benefits and immune resistance associated with immune checkpoint inhibitors; microRNA could play a vital role in these efforts. This study planned to identify differentially expressed miRNA molecules that may have prognostic value for clinical benefits. Patients with surgically operable regionally advanced melanoma were treated with neoadjuvant ipilimumab (10 mg/kg intravenously every 3 weeks × two doses) bracketing surgery. Tumor biospecimens were obtained at baseline and surgery, and microRNA (miRNA) expression profiling was performed on the tumor biopsies. We found that an expression profile consisting of a 4-miRNA signature was significantly associated with improved relapse-free survival (RFS). The signature consisted of biologically relevant molecules previously reported to have prognostic value in melanoma and other malignancies, including miR-34c, miR-711, miR-641, and miR-22. Functional annotation analysis of target genes for the 4-miRNA signature was significantly enriched for various cancer-related pathways, including cell proliferation regulation, apoptosis, the MAPK signaling pathway, and the positive regulation of T cell activation. Our results presented miRNAs as potential biomarkers that can guide the treatment of melanoma with immune checkpoint inhibitors. These findings warrant further investigation in relation to CTLA4 blockade and other immune checkpoint inhibitors. ClinicalTrials.gov NCT00972933.

Subjects

MeSH terms (MEDLINE)

MicroRNAsMelanomaHumansIpilimumabImmune Checkpoint InhibitorsNeoplasm Recurrence, LocalBiomarkersBiomarkers, Tumor

Author keywords

biomarkersimmunotherapymelanomamiRNAmicroRNA

Substances

IpilimumabMicroRNAsImmune Checkpoint InhibitorsBiomarkersBiomarkers, TumorMIRN641 microRNA, human

Authors and institutions

  • Cutaneous Oncology and Immunology Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
  • Hematology Department, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA.
  • Pathology and Laboratory Medicine Department, Allegheny Cancer Institute, Allegheny Health Network, Pittsburgh, PA 15524, USA.
  • Pathology Department, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
  • Oncologic Sciences Department, Morsani College of Medicine, University of South Florida, Tampa, FL 33602, USA.

ORCID profiles: Islam Eljilany, Lucas Santana-Santos

Funding

  • Moffitt Cancer Center
  • NCI NIH HHS
  • University of Pittsburgh
  • Bristol Myers Squibb
  • National Institutes of Healt
  • H. Lee Moffitt Cancer Center and Research Institute

Cite

APA

Kobeissi, I., Eljilany, I., Achkar, T., LaFramboise, W. A., Santana-Santos, L., & Tarhini, A. A. (2023). A Tumor and Immune-Related Micro-RNA Signature Predicts Relapse-Free Survival of Melanoma Patients Treated with Ipilimumab. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24098167

Vancouver

Kobeissi I, Eljilany I, Achkar T, LaFramboise WA, Santana-Santos L, Tarhini AA. A Tumor and Immune-Related Micro-RNA Signature Predicts Relapse-Free Survival of Melanoma Patients Treated with Ipilimumab. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24098167

BibTeX
@article{Kobeissi2023,
  author = {Kobeissi, Iyad and Eljilany, Islam and Achkar, Tala and LaFramboise, William A and Santana-Santos, Lucas and Tarhini, Ahmad A},
  title = {A Tumor and Immune-Related Micro-RNA Signature Predicts Relapse-Free Survival of Melanoma Patients Treated with Ipilimumab},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24098167}
}
Start for free →